Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma.

Takeshi Nonoshita, Yoshiyuki Shioyama, Naonobu Kunitake, Katsumasa Nakamura, Satoshi Nomoto, Ohga Saiji, Youichi Toriya, Minoru Ono, Hiroshi Honda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Between May 1993 and March 2004, 32 patients with T2N0 glottic squamous cell carcinoma received concurrent chemoradiotherapy as the primary treatment modality for larynx preservation. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gy (median total dose: 70 Gy). The chemotherapy regimen comprised carboplatin in 4 patients, carboplatin and tegafur and uracil in 7, carboplatin and futraful in 2, and futraful in 19 patients. Twenty-four patients received adjuvant chemotherapy with tegafur and uracil. Initial local tumor control was achieved in 30 patients (94%). The 5-year overall survival and 5-year local control rates were 97% and 70%, respectively. Univariate analysis revealed adjuvant chemotherapy as a significant prognostic factor for the local control rate (P = 0.038). The 5-year local control rate in patients treated or not treated with adjuvant chemotherapy was 82% and 42%, respectively. No significant differences in the local control rate were noted in overall treatment time, total radiation dose, age, and disease extension to the subglottis. With regard to adverse reactions, grade 3 neutropenia and grade 3 hepatotoxicity were observed in 1 and 2 patients, respectively. We observed no severe late complications (RTOG/EORTC criteria Grade 3-4) related to this combination therapy. Concurrent chemoradiotherapy and adjuvant chemotherapy was effective but with mild toxicity, and adjuvant chemotherapy significantly improved local control. We suggest the use of this combination therapy for achieving a local control of T2N0 glottic squamous cell carcinoma.

Original languageEnglish
Pages (from-to)26-31
Number of pages6
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume100
Issue number1
Publication statusPublished - Jan 1 2009

Fingerprint

Chemoradiotherapy
Adjuvant Chemotherapy
Tongue
Squamous Cell Carcinoma
Tegafur
Carboplatin
Uracil
Therapeutics
Larynx
Neutropenia
Radiotherapy
Radiation
Drug Therapy
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Retrospective analysis : concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. / Nonoshita, Takeshi; Shioyama, Yoshiyuki; Kunitake, Naonobu; Nakamura, Katsumasa; Nomoto, Satoshi; Saiji, Ohga; Toriya, Youichi; Ono, Minoru; Honda, Hiroshi.

In: Fukuoka igaku zasshi = Hukuoka acta medica, Vol. 100, No. 1, 01.01.2009, p. 26-31.

Research output: Contribution to journalArticle

Nonoshita, T, Shioyama, Y, Kunitake, N, Nakamura, K, Nomoto, S, Saiji, O, Toriya, Y, Ono, M & Honda, H 2009, 'Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma.', Fukuoka igaku zasshi = Hukuoka acta medica, vol. 100, no. 1, pp. 26-31.
Nonoshita, Takeshi ; Shioyama, Yoshiyuki ; Kunitake, Naonobu ; Nakamura, Katsumasa ; Nomoto, Satoshi ; Saiji, Ohga ; Toriya, Youichi ; Ono, Minoru ; Honda, Hiroshi. / Retrospective analysis : concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. In: Fukuoka igaku zasshi = Hukuoka acta medica. 2009 ; Vol. 100, No. 1. pp. 26-31.
@article{016f369f1b9946148a065936d13e3719,
title = "Retrospective analysis: concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma.",
abstract = "This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Between May 1993 and March 2004, 32 patients with T2N0 glottic squamous cell carcinoma received concurrent chemoradiotherapy as the primary treatment modality for larynx preservation. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gy (median total dose: 70 Gy). The chemotherapy regimen comprised carboplatin in 4 patients, carboplatin and tegafur and uracil in 7, carboplatin and futraful in 2, and futraful in 19 patients. Twenty-four patients received adjuvant chemotherapy with tegafur and uracil. Initial local tumor control was achieved in 30 patients (94{\%}). The 5-year overall survival and 5-year local control rates were 97{\%} and 70{\%}, respectively. Univariate analysis revealed adjuvant chemotherapy as a significant prognostic factor for the local control rate (P = 0.038). The 5-year local control rate in patients treated or not treated with adjuvant chemotherapy was 82{\%} and 42{\%}, respectively. No significant differences in the local control rate were noted in overall treatment time, total radiation dose, age, and disease extension to the subglottis. With regard to adverse reactions, grade 3 neutropenia and grade 3 hepatotoxicity were observed in 1 and 2 patients, respectively. We observed no severe late complications (RTOG/EORTC criteria Grade 3-4) related to this combination therapy. Concurrent chemoradiotherapy and adjuvant chemotherapy was effective but with mild toxicity, and adjuvant chemotherapy significantly improved local control. We suggest the use of this combination therapy for achieving a local control of T2N0 glottic squamous cell carcinoma.",
author = "Takeshi Nonoshita and Yoshiyuki Shioyama and Naonobu Kunitake and Katsumasa Nakamura and Satoshi Nomoto and Ohga Saiji and Youichi Toriya and Minoru Ono and Hiroshi Honda",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "100",
pages = "26--31",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "1",

}

TY - JOUR

T1 - Retrospective analysis

T2 - concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma.

AU - Nonoshita, Takeshi

AU - Shioyama, Yoshiyuki

AU - Kunitake, Naonobu

AU - Nakamura, Katsumasa

AU - Nomoto, Satoshi

AU - Saiji, Ohga

AU - Toriya, Youichi

AU - Ono, Minoru

AU - Honda, Hiroshi

PY - 2009/1/1

Y1 - 2009/1/1

N2 - This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Between May 1993 and March 2004, 32 patients with T2N0 glottic squamous cell carcinoma received concurrent chemoradiotherapy as the primary treatment modality for larynx preservation. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gy (median total dose: 70 Gy). The chemotherapy regimen comprised carboplatin in 4 patients, carboplatin and tegafur and uracil in 7, carboplatin and futraful in 2, and futraful in 19 patients. Twenty-four patients received adjuvant chemotherapy with tegafur and uracil. Initial local tumor control was achieved in 30 patients (94%). The 5-year overall survival and 5-year local control rates were 97% and 70%, respectively. Univariate analysis revealed adjuvant chemotherapy as a significant prognostic factor for the local control rate (P = 0.038). The 5-year local control rate in patients treated or not treated with adjuvant chemotherapy was 82% and 42%, respectively. No significant differences in the local control rate were noted in overall treatment time, total radiation dose, age, and disease extension to the subglottis. With regard to adverse reactions, grade 3 neutropenia and grade 3 hepatotoxicity were observed in 1 and 2 patients, respectively. We observed no severe late complications (RTOG/EORTC criteria Grade 3-4) related to this combination therapy. Concurrent chemoradiotherapy and adjuvant chemotherapy was effective but with mild toxicity, and adjuvant chemotherapy significantly improved local control. We suggest the use of this combination therapy for achieving a local control of T2N0 glottic squamous cell carcinoma.

AB - This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Between May 1993 and March 2004, 32 patients with T2N0 glottic squamous cell carcinoma received concurrent chemoradiotherapy as the primary treatment modality for larynx preservation. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gy (median total dose: 70 Gy). The chemotherapy regimen comprised carboplatin in 4 patients, carboplatin and tegafur and uracil in 7, carboplatin and futraful in 2, and futraful in 19 patients. Twenty-four patients received adjuvant chemotherapy with tegafur and uracil. Initial local tumor control was achieved in 30 patients (94%). The 5-year overall survival and 5-year local control rates were 97% and 70%, respectively. Univariate analysis revealed adjuvant chemotherapy as a significant prognostic factor for the local control rate (P = 0.038). The 5-year local control rate in patients treated or not treated with adjuvant chemotherapy was 82% and 42%, respectively. No significant differences in the local control rate were noted in overall treatment time, total radiation dose, age, and disease extension to the subglottis. With regard to adverse reactions, grade 3 neutropenia and grade 3 hepatotoxicity were observed in 1 and 2 patients, respectively. We observed no severe late complications (RTOG/EORTC criteria Grade 3-4) related to this combination therapy. Concurrent chemoradiotherapy and adjuvant chemotherapy was effective but with mild toxicity, and adjuvant chemotherapy significantly improved local control. We suggest the use of this combination therapy for achieving a local control of T2N0 glottic squamous cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=66149092282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149092282&partnerID=8YFLogxK

M3 - Article

C2 - 19378773

AN - SCOPUS:66149092282

VL - 100

SP - 26

EP - 31

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 1

ER -